%0 Journal Article %T Prognostic value of right ventricular ejection fraction in pulmonary arterial hypertension %+ Rétrovirus et Pathologie Comparée (RPC) %A Courand, P. Y. %A Pina Jomir, G. %A Khouatra, Chahéra %A Scheiber, C. %A Turquier, Ségolène %A Glerant, J. C. %A Mastroianni, B. %A Gentil, B. %A Blanchet-Legens, A. S. %A Dib, Alfred %A Derumeaux, G. %A Humbert, M. %A Mornex, Jean-François %A Cordier, Jean-Francois %A Cottin, Vincent %Z Fondation du souffle - Comite National contre les Maladies Respiratoires; Programme Hospitalier de Recherche Clinique; Hospices Civils de Lyon %< avec comité de lecture %@ 0903-1936 %J European Respiratory Journal %I European Respiratory Society %V 45 %N 1 %P 139-49 %8 2015 %D 2015 %R 10.1183/09031936.00158014 %M 25537560 %K Female %K Humans %K Male %K Adult %K Aged %K Middle Aged %K Hypertension %K Prospective Studies %K Treatment Outcome %K Follow-Up Studies %K Proportional Hazards Models %K Prognosis %K Angiography %K Echocardiography %K Kaplan-Meier Estimate %K Pulmonary Artery/*physiopathology %K Pulmonary/*diagnosis/*physiopathology %K Registries %K Right/physiopathology %K Stroke Volume %K Ventricular Dysfunction %Z Life Sciences [q-bio]Journal articles %X Right ventricle ejection fraction (RVEF) evaluated with magnetic resonance imaging is a strong determinant of patient outcomes in pulmonary arterial hypertension. We evaluated the prognostic value of RVEF assessed with conventional planar equilibrium radionuclide angiography at baseline and change 3-6 months after initiating pulmonary arterial hypertension-specific therapy. In a prospective cohort of newly diagnosed patients with idiopathic, heritable or anorexigen-associated pulmonary arterial hypertension, RVEF was measured at baseline (n=100) and 3-6 months after initiation of therapy (n=78). After a median follow-up of 4.1 years, 41 deaths occurred, including 35 from cardiovascular causes. Patients with a (median) baseline RVEF \\textgreater25% had better survival than those with a RVEF \\textless25% using Kaplan-Meier analysis (p=0.010). RVEF at baseline was an independent predictor of all-cause and cardiovascular mortality in adjusted Cox regression model (p=0.002 and p=0.007, respectively; HR 0.93 for both). Patients with stable or increased RVEF at 3-6 months had a trend for improved all-cause survival (HR 2.43, p=0.086) and had less cardiovascular mortality (HR 3.25, p=0.034) than those in whom RVEF decreased despite therapy. RVEF assessed with conventional planar equilibrium radionuclide angiography at baseline and change in RVEF 3-6 months after therapy initiation independently predict outcomes in patients with pulmonary arterial hypertension. %G English %L hal-02192923 %U https://univ-lyon1.hal.science/hal-02192923 %~ EPHE %~ UNIV-LYON1 %~ INRA %~ PSL %~ AGREENIUM %~ TEST-DEV %~ IVPC %~ UDL %~ UNIV-LYON %~ INRAE %~ EPHE-PSL